This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VIVUS Announces New Qsymia Offer

MOUNTAIN VIEW, Calif., March 5, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq:  VVUS) today announced a new program offering eligible patients a discount on Qsymia ® (phentermine and topiramate extended-release) capsules CIV for a limited time.  The Save Now! Program is available online exclusively at www.qsymia.com and provides patients with the opportunity to pay no more than $75 for 30 days of the recommended dose (Qsymia 7.5 mg/46 mg).  This represents up to $85 savings off the full retail price (which may vary by pharmacy) for this once daily therapy.

"We believe our Qsymia offer programs provide more patients struggling with obesity the opportunity to partner with their physicians to experience the benefits of Qsymia," said Peter Y. Tam, president of VIVUS.  "Our goal is to take every measure to make Qsymia more accessible to patients today as we continue to make progress toward achieving reimbursement for patients who qualify."

Qsymia is the only FDA-approved once daily combination therapy – and the first medication available in 13 years – for chronic weight management.

To obtain the offer, patients must have a valid prescription issued by a physician. The offer is limited to one per patient for the duration of the program.  Patients who qualify for the offer program are eligible to receive 30 days of the recommended dose (7.5 mg/46 mg) of Qsymia once daily for no more than $75.

It is suggested that new patients initiate therapy on the Qsymia starting dose of 3.75 mg/23 mg for 14 days and then increase to the Qsymia recommended dose of 7.5 mg/46 mg. This new offer complements the Qsymia Get Started! Free Trial Program, which provides eligible patients a free trial on a valid prescription for up to 14 capsules of the Qsymia starting dose (3.75 mg/23 mg). For more information, visit www.qsymia.com.

* Based on the full retail price of 30 capsules of Qsymia 7.5 mg/46 mg ( $85 savings), and the full retail price of 14 capsules of the Qsymia starting dose, 3.75 mg/23 mg ( $65 savings), for a total of $150.

About Qsymia Qsymia is approved in the U.S. and is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related medical condition such as high blood pressure, type 2 diabetes, or high cholesterol.

The effect of Qsymia on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of Qsymia in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,598.20 -91.66 -0.52%
S&P 500 2,098.04 -5.80 -0.28%
NASDAQ 5,115.3820 -12.8990 -0.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs